



## Hepatitis C Treatment Options

Mavyret™ is the preferred Hepatitis C product. Documentation on reason or contraindication must be provided when requesting other products.

Drug Therapy	Cirrhosis	G1a		G1b		G2		G3		G4		G5		G6	
		TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE
Mavyret™	No	8w	8w <sup>12</sup> , 12w <sup>14</sup> , 16w <sup>13</sup>	8w	8w <sup>12</sup> , 12w <sup>14</sup> , 16w <sup>13</sup>	8w	8w <sup>12</sup>	8w	16w <sup>12</sup>	8w	8w <sup>12</sup>	8w	8w <sup>12</sup>	8w	8w <sup>12</sup>
	No & Post Transplant <sup>^</sup>	12w	16w <sup>13</sup>	12w	16w <sup>13</sup>	12w	12w	12w	16w <sup>12</sup>	12w	12w	12w	12w	12w	12w
	Comp	8w	12w <sup>14</sup> , 16w <sup>13</sup>	8w	12w <sup>14</sup> , 16w <sup>13</sup>	8w	12w <sup>12</sup>	8w	16w <sup>12</sup>	8w	12w <sup>12</sup>	8w	12w <sup>12</sup>	8w	12w <sup>12</sup>
	Comp & Post Transplant <sup>^</sup>	12w	16w <sup>13</sup>	12w	16w <sup>13</sup>	12w	12w	12w	16w <sup>12</sup>	12w	12w	12w	12w	12w	12w
Zepatier™	No	12w <sup>t</sup>	12w <sup>t1</sup>	12w	12w <sup>1</sup>					12w	12w <sup>1a</sup>				
	Comp	12w <sup>t</sup>	12w <sup>t1</sup>	12w	12w <sup>1</sup>					12w	12w <sup>1a</sup>				
Zepatier™ + RBV	No	16w <sup>t</sup>	12- 16w <sup>p4</sup> , 16w <sup>t1</sup>		12w <sup>4</sup>						16w <sup>1b</sup>				
	Comp	16w <sup>t</sup>	12- 16w <sup>p4</sup> , 16w <sup>t1</sup>		12w <sup>4</sup>						16w <sup>1b</sup>				
Sovaldi®+ pegIFN + RBV	No	12w		12w						12w					
	Comp	12w		12w						12w					
Epclusa®	No	12w	12w <sup>5</sup>	12w	12w <sup>5,9</sup>	12w	12w <sup>2,5</sup>	12w	12w <sup>5~</sup>	12w	12w <sup>5</sup>	12w	12w <sup>5</sup>	12w	12w <sup>5</sup>
	Comp	12w	12w <sup>5</sup>	12w	12w <sup>5,9</sup>	12w	12w <sup>2,5</sup>	12w <sup>~</sup>	12w <sup>5</sup>	12w	12w <sup>5</sup>	12w	12w <sup>5</sup>	12w	12w <sup>5</sup>
	Decomp	24w		24w		24w		24w		24w		24w		24w	
Epclusa® + RBV	No								12w <sup>1~</sup>						
	Comp							12w <sup>~</sup>	12w <sup>1</sup>						
	Comp & Post Transplant <sup>^</sup>					12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>						
	Decomp	12w	12w <sup>5</sup> , 24w <sup>10</sup>	12w	12w <sup>5</sup> , 24w <sup>10</sup>	12w	12w <sup>5</sup> , 24w <sup>10</sup>	12w	12w <sup>5</sup> , 24w <sup>10</sup>	12w	12w <sup>5</sup> , 24w <sup>10</sup>	12w	12w <sup>5</sup> , 24w <sup>10</sup>	12w	12w <sup>5</sup> , 24w <sup>10</sup>



## Hepatitis C Treatment Options

Drug Therapy	Cirrhosis	G1a		G1b		G2		G3		G4		G5		G6	
		TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE	TN	TE
	Decomp & Post Transplant <sup>^</sup>					12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>						
Vosevi <sup>®</sup>	No		12w <sup>8,9</sup>		12w <sup>8</sup>		12w <sup>8</sup>		12w <sup>1#,6,9</sup>		12w <sup>6</sup>		12w <sup>6</sup>		12w <sup>6</sup>
	Comp		12w <sup>8,9</sup>		12w <sup>8</sup>		12w <sup>8</sup>	12w <sup>#</sup>	12w <sup>1,7,9</sup>		12w <sup>6</sup>		12w <sup>6</sup>		12w <sup>6</sup>
Vosevi <sup>®</sup> + RBV	No														
	Comp							12w <sup>8</sup>							
Harvoni <sup>®</sup>	No	12w	12w <sup>5</sup>	12w	12w <sup>5</sup>					12w	12w <sup>1</sup>	12w	12w <sup>1</sup>	12w	12w <sup>1</sup>
	No & low HCV RNA <sup>*</sup>	8w <sup>*</sup>		8w <sup>*</sup>											
	Comp	12w	24w <sup>5</sup>	12w	24w <sup>5</sup>					12w	12w <sup>1</sup>	12w	12w <sup>1</sup>	12w	12w <sup>1</sup>
	Decomp	24w		24w						24w		24w		24w	
Harvoni <sup>®</sup> + RBV	No		12w <sup>9x</sup>		12w <sup>9x</sup>										
	No & Post Transplant <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>					12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>
	Comp		12w <sup>5</sup>		12w <sup>5</sup>						12w <sup>1</sup>				
	Comp & Post Transplant <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>					12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>
	Decomp	12w	24w <sup>11</sup>	12w	24w <sup>11</sup>					12w	24w <sup>11</sup>	12w	24w <sup>11</sup>	12w	24w <sup>11</sup>
	Decomp & Post Transplant <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>					12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>	12w <sup>^</sup>
Sovaldi <sup>®</sup> + RBV	No					12w	12w <sup>1</sup>	24w	24w <sup>1</sup>						
	Comp					12w	12w <sup>1</sup>	24w	24w <sup>1</sup>						



## Hepatitis C Treatment Options

<sup>†</sup>For genotype 1a, Zepatier™ should be given alone for 12 weeks in patients without, or with ribavirin for 16 weeks in patients with, NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93.

<sup>‡</sup>Patients who have NS5A resistance-associated polymorphisms at amino acid positions 28, 30, 31, or 93 should have treatment extended to 16 weeks.

<sup>§</sup>Only for patients who have tested negative for the Q80K variant.

<sup>¶</sup>Except in patients who have failed simeprevir.

<sup>‡</sup>Except in patients who have failed NS3/4 protease inhibitor inclusive direct-acting antiviral combination regimens.

<sup>\*</sup>Harvoni® for 8 weeks may be considered in G1 treatment-naïve patients without cirrhosis who are non-black, HIV-uninfected, and have a pre-treatment HCV RNA < 6 million IU/ml.

<sup>~</sup>RAS testing for Y93H is recommended. If present, ribavirin should be added to the regimen.

<sup>#</sup>An alternative regimen for patients when Y93H is present.

<sup>^</sup>For patients who develop HCV infection post-liver transplantation.

<sup>1</sup>For patients who have failed pegIFN/RBV.

<sup>1a</sup>For patients who experienced virologic relapse after prior pegIFN/RBV therapy.

<sup>1b</sup>For patients who experienced on-treatment virologic failure while on prior pegIFN/

<sup>2</sup>For patients who have failed sofosbuvir + RBV.

<sup>3</sup>For patients who have failed sofosbuvir + RBV +/- pegIFN.

<sup>4</sup>For patients who have failed a NS3 protease inhibitor + pegIFN/RBV.

<sup>5</sup>For patients who have failed pegIFN/RBV +/- a NS3 protease inhibitor.

<sup>6</sup>For patients who have failed direct-acting antiviral (including NS5A Inhibitor).

<sup>7</sup>For patients who have failed direct-acting antiviral (not including NS5A Inhibitor).

<sup>8</sup>For patients who have failed a NS5A inhibitor.

<sup>9</sup>For patients who have failed a non-NS5A inhibitor, sofosbuvir-containing regimen.

<sup>10</sup>For patients who failed a sofosbuvir- or NS5A-containing regimen.

<sup>11</sup>For patients who failed a sofosbuvir-based treatment only.

<sup>12</sup>For patients who have failed PRS therapy (combination of pegIFN, RBV, and/or sofosbuvir) but no prior treatment experience with a NS3/4A protease inhibitor or NS5A inhibitor.

<sup>13</sup>For patients who have failed a regimen containing an NS5A inhibitor without prior treatment with a NS3/4A protease inhibitor.

<sup>14</sup>For patients who have failed a regimen containing a NS3/4A protease inhibitor without prior treatment with an NS5A inhibitor.

Key	
TN	Treatment-naïve
TE	Treatment-experienced
Comp	Compensated
Decomp	Decompensated
RBV	Ribavirin
pegIFN	Peginterferon
	Preferred First Line Therapy

### References:

<http://hcvguidelines.org/full-report-view>.

[http://packageinserts.bms.com/pi/pi\\_daklinza.pdf](http://packageinserts.bms.com/pi/pi_daklinza.pdf).

[http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/epclusa/epclusa\\_pi.pdf](http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf).

[http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/harvoni/harvoni\\_pi.pdf](http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf).

[http://www.rxabbvie.com/pdf/mavyret\\_pi.pdf](http://www.rxabbvie.com/pdf/mavyret_pi.pdf).

<http://www.olyzio.com/shared/product/olyzio/prescribing-information.pdf>.

[http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi\\_pi.pdf](http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf).

[http://www.rxabbvie.com/pdf/technivie\\_pi.pdf](http://www.rxabbvie.com/pdf/technivie_pi.pdf).

[http://www.rxabbvie.com/pdf/viekirapak\\_pi.pdf](http://www.rxabbvie.com/pdf/viekirapak_pi.pdf).

[http://www.rxabbvie.com/pdf/viekiraxr\\_pi.pdf](http://www.rxabbvie.com/pdf/viekiraxr_pi.pdf).

[http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/vosevi/vosevi\\_pi.pdf](http://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/vosevi/vosevi_pi.pdf).

[http://www.merck.com/product/usa/pi\\_circulars/z/zepatier/zepatier\\_pi.pdf](http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf).

[https://pdf.hres.ca/dpd\\_pm/00039964.PDF](https://pdf.hres.ca/dpd_pm/00039964.PDF).